Abstract:Background: Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major deficiencies including limited range of protection, total dependence on embryonated eggs for production, and time consuming for vaccine production. There is an urgent need to develop novel vaccine strategies to overcome these deficiencies.Methodology/Principal Findings: The major objective of this work was to develop a novel vaccine strategy combining recombinant haemagglutinin (HA) protein and a master cell (MC) activator C48/80 for intranasal immunization. We demonstrated in BALB/c mice that MC activator C48/80 had strong adjuvant activity when co-administered with recombinant HA protein intranasally. Vaccination with C48/80 significantly increased the serum IgG and mucosal surface IgA antibody responses against HA protein. Such increases correlated with stronger and durable neutralizing antibody activities, offering protection to vaccinated animals from disease progression after challenge with lethal dose of A/California/04/2009 live virus. Furthermore, protected animals demonstrated significant reduction in lung virus titers, minimal structural alteration in lung tissues as well as higher and balanced production of Th1 and Th2 cytokines in the stimulated splenocytes when compared to those without C48/80.Conclusions/Significance: The present study demonstrates that the novel vaccine approach of combining recombinant HA and mucosal adjuvant C48/80 is safe and effective in eliciting protective immunity in mice. Future studies on the mechanism of action of C48/80 and potential combination with other vaccine strategies such as prime and boost approach may help to induce even more potent and broad immune responses against viruses from various clades.

Intranasal Administration of Trivalent Influenza Virus with Rctb on Mice

Intranasal Administration of Trivalent Split Influenza Virus with Different Adjuvants on Balb/c Mice

Immune responses induced by intranasal immunization with inactivated influenza A split virus -antibody complex in mice

Immunity response induced by intranasal immunization with inactived human high pathogenic avian influenza vaccine

Study on preparation of liposome-encapsulated influenza split vaccine and its humoral responses in mice

Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus

Sublingual Vaccination with Live Influenza Virus Induces Better Protection Than Oral Immunization in Mice

Study on immunogenicity of recombinant lentivirus expressing trimeric HA of swine H1 N1 influenza virus

Intranasal Immunization Using Mannatide As a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

Broad spectrum immunity against influenza viruses elicited by intranasal vaccination with a new recombinant subunit vaccine (VAC2P.924)

Preliminary Study on Type I Interferon As a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein

The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response

Intranasal Immunization of Mice with Inactivated Virus and Mast Cell Activator C48/80 Elicits Protective Immunity Against Influenza H1 but Not H5.

Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice

Single-Dose Intranasal Immunisation with Novel Chimeric H1N1 Expressing the Receptor-Binding Domain of SARS-CoV-2 Induces Robust Mucosal Immunity, Tissue-Resident Memory T Cells, and Heterologous Protection in Mice

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges

Induction of protective immune response to intranasal administration of influenza virus‐like particles in a mouse model

Intranasal Immunization With Recombinant Ha And Mast Cell Activator C48/80 Elicits Protective Immunity Against 2009 Pandemic H1n1 Influenza In Mice

Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice

Evaluation of the cross-protection of the Vero cell-derived attenuated influenza vaccines with compound adjuvant, through intranasal immunization

Intranasal Vaccination with Recombinant TLR2-Active Outer Membrane Vesicles Containing Sequential M2e Epitopes Protects against Lethal Influenza a Challenge